Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company reported Ingrezza Q4 about 1% below consensus estimates and missed on non-GAAP EPS, primarily due to increasing competitive pressure and payors dynamics. These factors motivate the company’s lower-than-expected FY25 Ingrezza sales guidance, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
- Neurocrine price target lowered to $148 from $154 at RBC Capital
- Neurocrine price target lowered to $147 from $157 at Wedbush
- Hold Rating on Neurocrine Due to Below-Expectations Financial Performance and Conservative Sales Guidance
- Neurocrine price target lowered to $185 from $190 at H.C. Wainwright